Skip to main content
Fig. 7 | BMC Nephrology

Fig. 7

From: Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model

Fig. 7

Spironolactone (SPL) improves endothelial dysfunction in advanced glycation end products (AGEs) –stimulated human aortic endothelial cells (HAECs) through sirtuin-3 (SIRT3) protein mediation. (a) Downregulation of SIRT3 was noted in AGEs-stimulated HAECs. The addition of SPL at concentrations of 1 μM and 10 μM improved the SIRT3 protein expression. (b) SPL increased phospho-endothelial nitric oxide synthase (p-eNOS) activation at a concentration of 10 μM in AGEs-stimulated HAECs. However, pretreatment of AGEs-stimulated HAECs with tenovin-6 at a concentration of 1 μM abrogated the effect of SPL on the p-eNOS activation. * any groups compared with the vehicle, p < 0.05; # any groups compared with the AGEs group, p < 0.05

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us